WO2021202990A3 - Methods for the treatment of betacoronavirus infections - Google Patents

Methods for the treatment of betacoronavirus infections Download PDF

Info

Publication number
WO2021202990A3
WO2021202990A3 PCT/US2021/025567 US2021025567W WO2021202990A3 WO 2021202990 A3 WO2021202990 A3 WO 2021202990A3 US 2021025567 W US2021025567 W US 2021025567W WO 2021202990 A3 WO2021202990 A3 WO 2021202990A3
Authority
WO
WIPO (PCT)
Prior art keywords
infections
betacoronavirus
treatment
methods
cov
Prior art date
Application number
PCT/US2021/025567
Other languages
French (fr)
Other versions
WO2021202990A2 (en
Inventor
Derek William GILROY
Original Assignee
TEPPER, Mark, Allan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TEPPER, Mark, Allan filed Critical TEPPER, Mark, Allan
Publication of WO2021202990A2 publication Critical patent/WO2021202990A2/en
Publication of WO2021202990A3 publication Critical patent/WO2021202990A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention features the use of a p38 inhibitor for the treatment and prophylaxis of severe symptoms of betacoronavirus infections, such as infections by SARS-CoV-2, SARS-CoV-1, MERS-CoV, and related viruses.
PCT/US2021/025567 2020-04-03 2021-04-02 Methods for the treatment of betacoronavirus infections WO2021202990A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063004746P 2020-04-03 2020-04-03
US63/004,746 2020-04-03

Publications (2)

Publication Number Publication Date
WO2021202990A2 WO2021202990A2 (en) 2021-10-07
WO2021202990A3 true WO2021202990A3 (en) 2021-12-02

Family

ID=77929468

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/025567 WO2021202990A2 (en) 2020-04-03 2021-04-02 Methods for the treatment of betacoronavirus infections

Country Status (1)

Country Link
WO (1) WO2021202990A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023280911A1 (en) * 2021-07-06 2023-01-12 Westfälische Wilhelms-Universität Münster P38-inhibitors for the treatment of coronavirus infections and/or covid-19 cytokine storm

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100227881A1 (en) * 2006-08-09 2010-09-09 Juan Francisco Caturla Javaloyes 1,7-naphthyridine derivatives as p38 map kinase inhibitors
US20110046109A1 (en) * 2000-10-23 2011-02-24 Glaxosmithkline Llc 2,4,8-trisubstituted-8h-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy
US20190125735A1 (en) * 2015-12-29 2019-05-02 Board Of Regents, The University Of Texas System Inhibition of p38 mapk for the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110046109A1 (en) * 2000-10-23 2011-02-24 Glaxosmithkline Llc 2,4,8-trisubstituted-8h-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy
US20100227881A1 (en) * 2006-08-09 2010-09-09 Juan Francisco Caturla Javaloyes 1,7-naphthyridine derivatives as p38 map kinase inhibitors
US20190125735A1 (en) * 2015-12-29 2019-05-02 Board Of Regents, The University Of Texas System Inhibition of p38 mapk for the treatment of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHANNAPPANAVAR ET AL.: "Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology", SEMIN IMMUNOPATHOL, vol. 39, 2017, pages 529 - 539, XP037066447, DOI: 10.1007/s00281-017-0629-x *
GUBERINA ET AL.: "A patient with severe respiratory failure caused by novel human coronavirus", INFECTION, vol. 42, 2014, pages 203 - 206, XP037069359, DOI: 10.1007/s15010-013-0509-9 *
HABIB ABDULRAHMAN MOHAMMED G., ALI MOHAMED ABD ELGHAFOUR, ZOUAOUI BAHA R., TAHA MUSTAFA AHMED H., MOHAMMED BASSEM SAHSAH, SAQUIB N: "Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection", BMC INFECTIOUS DISEASES, vol. 19, no. 1, 1 December 2019 (2019-12-01), XP055880699, DOI: 10.1186/s12879-019-4555-5 *
LIM ET AL.: "Middle East Respiratory Syndrome coronavirus (MERS CoV): Update 2013", CURR INFECT DIS REP, vol. 15, 2013, pages 295 - 298, XP037068637, DOI: 10.1007/s11908-013-0344-2 *

Also Published As

Publication number Publication date
WO2021202990A2 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
WO2020243415A3 (en) Tead inhibitors and uses thereof
WO2020120714A8 (en) Compositions comprising bacterial strains
WO2018042343A3 (en) Compounds that inhibit 3c and 3cl proteases and methods of use thereof
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
SA520412335B1 (en) Oxy-fluoropiperidine derivatives as kinase inhibitor
PH12021551268A1 (en) 3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same
WO2021022163A3 (en) Compounds and uses thereof
WO2020171727A3 (en) Mucoadhesive compositions and uses thereof
MX2021002719A (en) Cannabinoids for the treatment of gram-positive infections including antibiotic-resistant bacterial strains.
WO2021155321A3 (en) Compounds and uses thereof
MX2021006011A (en) An aurora a kinase inhibitor for use in the treatment of neuroblastoma.
WO2021212021A3 (en) Coronavirus antibodies and methods of use thereof
WO2021089768A3 (en) Treatment and prevention of a neurodegenerative disorder
WO2021202990A3 (en) Methods for the treatment of betacoronavirus infections
WO2022063869A3 (en) Compounds for the treatment of viral infections
MX2021007544A (en) Novel crystalline forms of an nrtti compound.
WO2021214348A3 (en) Compounds for electronic devices
WO2019165158A8 (en) Il-6 inhibitors and methods of treatment
MX2022004912A (en) Novel substituted condensed ring compound.
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
WO2023285654A3 (en) Compounds for the treatment of covid-19
WO2018187623A8 (en) Crystalline forms of (s)-afoxolaner
WO2018101595A3 (en) Escherichia coli bacteriophage esc-cop-9 and use for inhibiting proliferation of pathogenic escherichia coli thereof
WO2021226037A8 (en) Treatment of viral infections
MX2021013634A (en) Stable albuvirtide compositions.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21779587

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21779587

Country of ref document: EP

Kind code of ref document: A2